SMALL MOLECULE THERAPEUTICS

2677 Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer
Rebecca A. Previs, Guillermo N. Armaiz-Pena, Yvonne C. Lin, Ashley N. Davis, Sunila Pradeep, Heather J. Dalton, Robert L. Coleman, and Anil K. Sood

2687 Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
Kazuharu Kai, Kimie Kondo, Xiaoping Wang, Xuemei Xie, Mary Kathryn Pitner, Monica E. Reyes, Angie M. Torres-Adorno, Hiroko Masuda, Gabriel N. Hortobagyi, Chandra Bartholomeusz, Hideyuki Saya, Debu Tripathy, Subrata Sen, and Naoto T. Ueno

2700 Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors
Steven R. Whittaker, Glenn S. Cowley, Steve Wagner, Flora Luo, David E. Root, and Levi A. Garraway

2712 Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma
Matthias Ilmer, Agnès Garnier, Jody Vykoukal, Eckhard Alt, Dietrich von Schweinitz, Roland Kappler, and Michael Berger

2722 Silibinin Preferentially Radiosensitizes Prostate Cancer by Inhibiting DNA Repair Signaling
Dhanya K. Nambiar, Paulraj Rajamani, Gagan Deep, Anil K. Jain, Rajesh Agarwal, and Rana P. Singh

2735 Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

LARGE MOLECULE THERAPEUTICS

2782 High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study
Sylvain Manfredi, Olivier Bouché, Philippe Rougier, Laetitia Dahon, Marie Anne Loriot, Thomas Aparicio, Pierre Luc Ettiene, Jean Pierre Lalaguer, Cedric Lécaillé, Jean Louis Legoux, Karine Le Malicot, Emilie Maillard, Thierry Lecomte, Faiza Khemissa, Gilles Breyacher, Pierre Michel, Emmanuel Mitry, and Laurent Bedenne

2789 Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors
Ronit Mazor, Jingli Zhang, Lackman Addissie, Prince Awuah, Richard Beers, Rafat Hassan, and Ira Pastan
Systemic Administration and Targeted
Radiosensitization via Chemically Synthetic
Aptamer–siRNA Chimeras in Human Tumor
Xenografts
Xiaohua Ni, Yonggang Zhang, Kenji Zennami,
Mark Castanares, Amarnath Mukherjee, Raju R. Raval,
Haoming Zhou, Theodore L. DeWeese, and
Shawn E. Lupold

A TORC2–Akt Feed-Forward Topology
Underlies HER3 Resiliency in HER2-Amplified
Cancers
Dhara N. Amin, Deepika Ahuja, Paul Yaswen, and
Mark M. Moasser

PARP Inhibitors Sensitize Ewing Sarcoma
Cells to Temozolomide-Induced Apoptosis
via the Mitochondrial Pathway
Florian Engert, Cornelius Schneider,
Lilly Magdalena Weiß, Marie Probst, and Simone Fulda

ERK Signal Suppression and Sensitivity to
CH5183284/Debio 1347, a Selective FGFR
Inhibitor
Yoshito Nakanishi, Hideaki Mizuno, Hitoshi Sase,
Toshihiko Fuji, Kiyoko Sakata, Nukinori Akiyama,
Yuko Aoki, Masahiro Aoki, and Nobuya Ishii

Potentiation of Carboplatin-Mediated DNA
Damage by the Mdm2 Modulator Nutlin-3a in a
Humanized Orthotopic Breast-to-Lung
Metastatic Model
Eva Tonsing-Carter, Barbara J. Bailey,
M. Reza Saadatzaeh, Jixin Ding, Haiyan Wang,
Anthony L. Sinn, Kacie M. Peterman,
Taisiaha K. Spragins, Jayne M. Silver, Alyssa A. Sprouse,
Taxiarchis M. Georgiadis, T. Zachary Gunter,
Eric C. Long, Robert E. Minto, Clayton Lau,
James A. Bankson, and Stephen T. Lai

Genome-Wide Identification of a Methylation
Gene Panel as a Prognostic Biomarker in
Nasopharyngeal Carcinoma
Wei Jiang, Na Liu, Xiao-Zhong Chen, Ying Sun, Bin Li,
Xian-Yue Ren, Wei-Feng Qin, Ning Jiang, Ya-Fei Xu,
Ying-Qin Li, Jian Ren, William CS Cho, Jing-Ping Yun,
Jing Zeng, Li-Zhi Liu, Li Li, Ying Guo, Hai-Qiang Mai,
Mu-Sheng Zeng, Tie-Rang Kang, Wei-Hua Jia,
Ying Guo, Hai-Qiang Mai, and Jun Ma

Severely Impaired and Dysregulated
Cytochrome P450 Expression and Activities
in Hepatocellular Carcinoma: Implications
for Personalized Treatment in Patients
Tongmeng Yan, Linlin Lu, Cong Xie, Jianwei Chen,
Xiaojuan Peng, LiJun Zhu, Ying Wang, Qiang Li,
Jian Shi, Fuyuan Zhou, Ming Hu, and Zhongqiu Liu

Assessment of BRAF V600E Status in
Colorectal Carcinoma: Tissue-Specific
Discordances between Immunohistochemistry
and Sequencing
Jeannelyn S. Estrella, Michael T. Tetzlaff,
Roland L. Bessett Jr, Keyur P. Patel,
Michelle D. Williams, Jonathan L. Curry, Asif Rashid,
Stanley R. Hamilton, and Russell R. Broaddus

Clinical and Translational Assessment of
VEGFR1 as a Mediator of the Premetastatic
Niche in High-Risk Localized Prostate Cancer
Sumanta Kumar Pal, Winston Vuong, Wang Zhang,
Jiehui Deng, Xueli Liu, Courtney Carmichael,
Nora Ruel, Manasvi Pinnamaneni,
Pozemeslaw Twardowski, Clayton Lau, Hua Yu,
Robert A. Figlin, Neeraj Agarwal, and Jeremy O. Jones
ABOUT THE COVER

The cover image shows the structural model of LMB-T20, a highly potent recombinant immunotoxin consisting of an antimesothelin Fv fused to a portion of Pseudomonas exotoxin A. The toxin has a deletion of domain II and six point mutations in domain III that delete or greatly suppress the eight T-cell epitopes. For details, see the article by Mazor and colleagues on page 2789.